









## HEMNET Forum

**L**th

November 3<sup>rd</sup> – 5<sup>th</sup> 2022

Hôtel Bracelo Anfa Casablanca

## PROGRAM

## HEMNET FORUM IV: MOROCCO 3-5 November, 2022 - Barcelo, Casablanca

DAY 1: THURSDAY, 3 NOVEMBER **Opening Ceremony** 

19:00 – 20:00

20:00

10:00 – 10:30

10:45 – 11:10

12:00 - 13:00

17:00 - 17:15

18:15 - 18:30

8:30 - 10:30

10:30 – 11:00

11:30 – 11:45

11:45 - 12:00

12:45 - 13:45

**Opening Ceremony and Exhibition Opening** Chair of the 4th HEMNET Forum – Mohammed El-Khorassani (Morocco)

- Chair of the HEMNET Group Magdy El-Ekiaby (Egypt) President of AMH - Lahsen Mrani Alaoui (Morocco)
- . WFH Chief Executive Officer Alain Baumann (Canada) Ministry of Health and Social Protection of Morocco

DAY 2: FRIDAY, 4 NOVEMBER

Life Journey of PWH: Personalized Treatment

SESSION I: The Beginning: Infancy and Pediatrics for Persons with Hemophilia

DINNER

**Moderator: Emna Gouider (Tunisia)** 

09:00 – 09:30 Initiating Treatment: A Doctor's Decision (Clinical Presentations)

 Miftah Al-Sahati (Libya) Hadeel Saleh (Kuwait)

Selim Nekkal (Algeria)

09:30 - 10:00 Panel Discussion: When to Start Therapy? What Protocols to Follow?

**SESSION II - Adolescence** 

Moderators: Mohammed Khorassani (Morocco) and Mona Hamdy (Egypt)

COFFEE BREAK

10:30 – 10:45 Challenges of Transition from Pediatric to Adult HTCs: The Experience of Morocco –

A Surgeon's Perspective: Walid Saied (Tunisia)

Jihane Belayachi (Morocco)

Psycho-Social Challenges and Considerations for Adolescents - Frederica Cassis (Brazil)

**AMANYS** 

Roche

How to Manage MSK Complications in Adolescents and Young Adults -11:10 - 11:40

11:40 - 12:00 Discussion

**LUNCH INDUSTRY SYMPOSIUM - AMANY'S PHARMA** 

Immune Tolerance Induction (ITI) - Emna Gouider (Tunisia) 13:00 - 15:00 PRAYER BREAK

**SESSION III - Inhibitors** 

Moderator: Rhizlane Berrady (Morocco) and Tahira Zafar (Pakistan) 15:00 - 15:15 Diagnosis and Management of Acquired Hemophilia: What is the Region's Experience -

Tarek Owaidah (Saudi Arabia) Egypt's Experience in ITI – Mohsen Al-Alfy (Egypt) 15:15 - 15:25

How is Emicizumab Used in the Eastern Mediterranean Region? Real Life Issues -15:25 - 15:40

Magdy El-Ekiaby (Egypt) 15:40 - 16:00 **Moderated Discussion** 

**INDUSTRY SYMPOSIUM - ROCHE** 16:00 - 17:00 Real World Data Responses to Key Clinical Questions Relating

COFFEE BREAK

How Can HTCs support PWH?

**Moderated Discussion** 

SESSION IV - Adulthood and Ageing in the Era of Different Therapeutics

Moderators: Nisrine Khoubila (Morocco) and Ahmad Tarawah (Saudi Arabia) 17:15 – 17:35 Lifestyles in the Young Adult Stage – Marriage, Work and Employment:

to Hemophilia A Management - Alok Srivastava (India)

 HTC perspective - Frederica Cassis (Brazil) PWH Perspective - Walid Qubaisi (UAE)

17:35 – 17:55 Living Longer: Ageing Complications – Ali Taher (Lebanon)

17:55 – 18:15 How to Manage MSK Complications in Adolescents and Young Adults: A Physiotherapist's Perspective – Kaouther Zahra (Tunisia)

20:00 DINNER

DAY 3: SATURDAY, 5 NOVEMBER Rare Bleeding Disorders

SESSION V - Women with Bleeding Disorders: Clinical Case Studies Moderators: Claudia Khayat (Lebanon), Anis Fadhlaoui (Tunisia) and Frederica Cassis (Brazil)

 FXIII Deficiency - Tahani Ali (Syria) Afibrinogenemia - Claudia Khayat (Lebanon)

 Glanzmann Thrombasthenia - Ons Ghali (Tunisia) VWD Type 3 - Tahira Zafar (Pakistan)

COFFEE BREAK

Clinical Case Presentations and Moderated Discussion:

The WFH World Bleeding Disorders Registry (WBDR) - Emily Ayoub (Canada) 11:00 – 11:20

Claudia Khayat (Lebanon)

11:20 – 11:30 Discussion

**SESSION VI - WFH Session** 

**Moderator: Alain Baumann** 

**SESSION VII - Von Willebrand Disease (VWD) Moderator: Magdy El-Ekiaby (Egypt)** 

Do Obstetricians Know About VWD? - Jolana Schmiedl (Switzerland)

Current Models of Hemophilia Care in Middle East - Magdy Ekiaby (Egypt)

Overview of Congenital Dysfibrinogenemia- Emna Gouider (Tunisia)

VWD: Need for Better Diagnosis and Management- Claudia Khayat (Lebanon)

Education, Outreach, Diagnosis and Treatment (Survey on Country Experiences) -

12:00 - 12:30 Panel Discussion: How to Adapt the Recent VWD Guidelines to Contexts of Developing Countries? 12:30 - 12:45 BREAK

**CSL Behring** Chairman: Mohamed Elkhorassani (Morocco) Status of Rare Hemostasis Disorders in the Middle East: How Do We Keep Up with the Times?

 Q&A session: Panelists **SESSION VIII - Rare Bleeding Disorders: Multi HTC Clinical Cases** 

Moderators: Nawal Al Mashaykhi (Oman) and Houssein Mahmal (Morocco)

**LUNCH SYMPOSIUM - CSL BEHRING** 

Introduction - Mohamed El Khorassani

Factor XIII - Akbar Dorgalaleh (Iran)

Factor X - Safaa Mohammad (Iraq)

15:35 - 16:00 | COFFEE BREAK

**SESSION X - Closing Session** 

DINNER

17:30 – 17:45

20:00

**SESSION IX - Best Submitted Abstracts** 

Magy Abdelwahab (Egypt)

Sarra Fekih Salem (Tunisia)

Clinical Case Presentations and Moderated Discussion 13:45 - 15:05 Factor VII - Sarra Benmiloud (Morocco) Fibrinogen - Claudia Khayat (Lebanon)

**INDUSTRY SYMPOSIUM - BPL** 15:05 - 15:35 Factor X Deficiency - Steve Austin (United Kingdom) Bio Products Laboratory

16:00 - 17:30 **Abstract Presentations:**  Hemophilic Arthropathy: Objective Scores for Assessment - Ilham Youssry (Egypt) Menorrhagia in Egyptian Adolescent Girls with Inherited Bleeding Disorders: A Single Centre Study -

Moderators: Mustapha Al-Falah (Jordan) and Assad Haffar (WFH)

 Difficulty of Hemophilia Care in Developing Countries: Experience of the Hemophilia Centre at the Mohammed VI University Hospital in Marrakech - Rajaa Tissir (Morocco)

> Acquired Hemophilia "A" Associated with Anti-Phospholipid Syndrome: A Case Report – Rajaa Tissir (Morocco)

Low dose Prophylaxis: After 10 Years of Follow-up - Ons Ghali (Tunisia)

Pediatric Population of PWH at the Hemophilia Treatment Center of Aziza Othmana Hospital -

Molecular Defects of Congenital Deficiencies of Fibrinogen in Tunisia - Hejer Elmahmoudi (Tunisia)

Closing Remarks

SPONSORS



CSL Behring



Bio Products Laboratory

secretariat@hemnetforum.com

Mobile: +212 777 280 378 WhatsApp: +216 22413 410

VALVOVOVALVOVOVALVOVOVA